https://www.selleckchem.com/pr....oducts/crenolanib-cp
After adjusting for risk status, those who received RT plus adjuvant chemotherapy had superior PFS compared to RT plus neoadjuvant chemotherapy [HR = 0.46 (0.22, 0.95), = .0357]. Within a subgroup for whom detailed clinical data were available, those who received RT plus adjuvant chemotherapy had improved PFS compared to RT only [HR = 0.24 (0.074-0.76), = .016]. The substitution of cisplatin for carboplatin and the elimination of vincristine did not negatively affect outcomes. This is the largest single-institution retrospe
Like
Comment
Share
